Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Slaveyko N, Djambazov"'
Autor:
Slaveyko N. Djambazov, Toni Vekov, Evgeni Mekov, Dimitar Kostadinov, Ljubliana T. Konteva, Georgi S. Slavchev, Rosen Petkov
Publikováno v:
Folia Medica, Vol 60, Iss 3, Pp 397-401 (2018)
Background: Patients with non-small-cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) rearrangement mutation are found to be 3–13%. Aim: To evaluate the prevalence of ALK mutations in EGFR-negative NSCLC patients in Bulgaria. Materials
Autor:
Toni Vekov, Slaveyko N. Djambazov
Publikováno v:
Journal of Biomedical and Clinical Research. 9:101-106
Summary Health technology assessment (HTA) isaprocess, which should answer the question“Isagiven health technology/medication worth its price for the value it provides?” In the spirit of the amendments to the Bulgarian Health Insurance Act and in
Publikováno v:
The European journal of health economics : HEPAC : health economics in prevention and care. 21(8)
The present study aimed to provide normative data for the EQ-5D-5L questionnaire in Bulgaria, based on a nationally representative sample. Random sampling was used. In September 2018, a total of 1005 respondents (aged 18–89 years) completed the sel
Publikováno v:
Journal of comparative effectiveness research. 8(7)
Hepatitis C virus (HCV) is a positive-stranded RNA virus which belongs to the family of Flaviviridae , predominantly infecting liver hepatocytes. HCV infection is a major cause for morbidity worldwide. Aim: The primary objective was to evaluate the c
Background The relevance of studies focusing on patient satisfaction becomes imperative for patients with cancer, who often face major changes in their lifestyles. Their perceived uncertainty in illness and their personal experiences with the service
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4cbe916a78ff03ed00259233db3d1a83
http://hdl.handle.net/11570/3162164
http://hdl.handle.net/11570/3162164
Cost-effectiveness analysis of the health technologies for treatment of chronic lymphocytic leukemia
Autor:
Toni Vekov, Slaveyko N. Djambazov
Publikováno v:
Annual for Hospital Pharmacy. 2:21
Представени са анализ и оценка на целевите здравни технологии (антитела и киназни инхибитори), използвани за лечение на хронична лимфоц
Publikováno v:
World hospitals and health services : the official journal of the International Hospital Federation. 45(3)
Clinical paths in Bulgaria are used not as a method for quality assessment, but as an instrument to fund hospitals. Their use and incompleteness cause limited access of all Bulgarian citizens to the international treatment guidelines. That way qualit
Autor:
Toni Y, Vekov, Mladen V, Grigorov, Ventsislav T, Georgiev, Slaveyko N, Djambazov, Ladislav, Groch, Ota, Hlinomaz, Jan, Sitar, Mihail, Rezek
Publikováno v:
World hospitals and health services : the official journal of the International Hospital Federation. 45(2)
Cardiovascular mortality in Bulgaria has increased for the last 25 years, contrary to the rest of the EU countries. One of the reasons is high in-hospital mortality due to acute myocardial infarction. The Bulgarian Cardiac Institute has established a